Induced proximity-based therapeutics for advanced prostate cancer
Metastatic castration-resistant prostate cancers (mCRPC) remain dependent on androgen receptor (AR) signaling despite resistance to androgen-deprivation and AR-targeted therapies. Induced proximity-based therapeutics employ event-driven pharmacology to target AR, potentially overcoming resistance mechanisms. Herein, we highlight recent advances in induced proximity strategies targeting AR in mCRPC.
Authors
- John Ching
- William D. Figg
- Cindy H. Chau
Institutions
- Office of the Director (US)
- National Cancer Institute (US)
Publication Details
- Journal
- npj Drug Discovery.
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1038/s44386-026-00062-5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health